Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3476253 | 0.99 | RAB9A (0.43) | RAB9ANPC1ALDH1A1SMN1; SMN2BAZ2B | |
| SCHEMBL3477340 | 0.93 | HRH4 (0.43) | RAB9ANPC1ALDH1A1SMN1; SMN2BAZ2B | |
| SCHEMBL3477583 | 0.89 | LMNA (0.41) | ALDH1A1SMN1; SMN2BAZ2BPOLBLMNA | |
| SCHEMBL3477811 | 0.87 | KDM4E (0.44) | ALDH1A1SMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL3477116 | 0.85 | MAPK1 (0.43) | BAZ2BPOLBLMNAMAPTTDP1 | |
| SCHEMBL3477440 | 0.84 | LMNA (0.43) | ALDH1A1SMN1; SMN2LMNAMAPTTDP1 | |
| SCHEMBL3477657 | 0.84 | HTT (0.44) | RAB9ANPC1ALDH1A1LMNAMAPT | |
| SCHEMBL3477114 | 0.84 | MAPT (0.51) | ALDH1A1SMN1; SMN2LMNAMAPTSIRT2 | |
| SCHEMBL3477999 | 0.83 | EPHX2 (0.45) | RAB9ANPC1ALDH1A1TDP1 | |
| SCHEMBL3476315 | 0.81 | CCKBR (0.39) | ALDH1A1SMN1; SMN2POLBLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179122-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2010-07-15 | — | — | US | claimed |
| US-20100179122-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179122-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | RNGTT, RTF1, POLR1E | RAB9A 1995/4885NPC1 1185/4885ALDH1A1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.